指南与共识消化系统肿瘤

晚期肝细胞癌的系统治疗:ASCO指南

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.
指南 / 共识 · J Clin Oncol · 2020-11-16

ASCO召集专家小组对2007-2020年发表的III期随机对照试验进行系统综述,制定晚期肝细胞癌系统治疗指南。共纳入9项III期随机对照试验,推荐阿替利珠单抗+贝伐珠单抗作为大多数晚期HCC患者的一线治疗,并给出了后续治疗选择。

要点

  • 阿替利珠单抗+贝伐珠单抗可作为大多数晚期HCC(Child-Pugh A级、ECOG PS 0-1)的一线治疗。
  • 存在阿替利珠单抗和/或贝伐珠单抗禁忌时,索拉非尼或仑伐替尼可作为一线治疗。
  • 一线阿替利珠单抗+贝伐珠单抗后,二线可推荐TKI;一线索拉非尼或仑伐替尼后,二线可选卡博替尼、瑞戈非尼、雷莫西尤单抗或帕博利珠单抗/纳武利尤单抗等。

核心结论

  • 对于大多数晚期HCC、Child-Pugh A级、ECOG PS 0-1且食管静脉曲张已按机构指南管理的患者,可提供阿替利珠单抗+贝伐珠单抗作为一线治疗。

研究设计与样本

  • ASCO召集专家小组,对2007-2020年发表的关于晚期HCC系统治疗的III期随机对照试验进行系统综述。
  • 共纳入9项符合入组标准的III期随机对照试验。

主要发现

  • 共9项III期随机对照试验符合纳入标准。

关键数值与推荐

  • 阿替利珠单抗+贝伐珠单抗可作为大多数晚期HCC(Child-Pugh A级、ECOG PS 0-1)的一线治疗,但需先按机构指南管理食管静脉曲张(若存在)。
  • 当阿替利珠单抗和/或贝伐珠单抗存在禁忌时,可提供索拉非尼或仑伐替尼作为一线治疗(Child-Pugh A级、ECOG PS 0-1)。
  • 一线阿替利珠单抗+贝伐珠单抗后,在获得更好数据前,可推荐TKI作为二线治疗用于合适候选者。
  • 一线索拉非尼或仑伐替尼后,二线 options 包括卡博替尼、瑞戈非尼(既往耐受索拉非尼者)、雷莫西尤单抗(α-胎蛋白≥400 ng/mL)或阿替利珠单抗+贝伐珠单抗(一线未获得该选项者)。
  • 索拉非尼或仑伐替尼后,帕博利珠单抗或纳武利尤单抗也是合适患者的合理选择;纳武利尤单抗+伊匹木单抗可作为二线或三线选项进行讨论。

临床怎么用

  • 临床决策时应根据Child-Pugh分级、ECOG PS、食管静脉曲张管理情况以及药物可及性选择一线和二线系统治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with advanced hepatocellular carcinoma (HCC). METHODS: ASCO convened an Expert Panel to conduct a systematic review of published phase III randomized controlled trials (2007-2020) on systemic therapy for advanced HCC and provide recommended care options for this patient population. RESULTS: Nine phase III randomized controlled trials met the inclusion criteria. RECOMMENDATIONS: Atezolizumab + bevacizumab (atezo + bev) may be offered as first-line treatment of most patients with advanced HCC, Child-Pugh class A liver disease, Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1, and following management of esophageal varices, when present, according to institutional guidelines. Where there are contraindications to atezolizumab and/or bevacizumab, tyrosine kinase inhibitors sorafenib or lenvatinib may be offered as first-line treatment of patients with advanced HCC, Child-Pugh class A liver disease, and ECOG PS 0-1. Following first-line treatment with atezo + bev, and until better data are available, second-line therapy with a tyrosine kinase inhibitor may be recommended for appropriate candidates. Following first-line therapy with sorafenib or lenvatinib, second-line therapy options for appropriate candidates include cabozantinib, regorafenib for patients who previously tolerated sorafenib, or ramucirumab (for patients with α-fetoprotein ≥ 400 ng/mL), or atezo + bev where patients did not have access to this option as first-line therapy. Pembrolizumab or nivolumab are also reasonable options for appropriate patients following sorafenib or lenvatinib. Consideration of nivolumab + ipilimumab as an option for second-line therapy and third-line therapy is discussed. Further guidance on choosing between therapy options is included within the guideline. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. J Clin Oncol. 2020. PMID: 33197225. doi:10.1200/JCO.20.02672

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。